Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and Expectations

Table 2

Responses in clinical trials.

Drug	𝑁	CR	PR	SD
Figitumumab
Phase I [67]	15	1 (7%)	1 (7%)	6 (40%)
Phase II [68]	106	0	15 (14%)	25 (24%)
R1507 Phase I
Phase I [73]	9	0	2 (22%)	2 (22%)
Phase II [74]	111	1 (1%)	7 (6%)	17 (15%)
Ganitumumab
Phase I [75]	12	1 (8%)	1 (8%)	NA/NR
Phase II [76]	19	0	1 (5%)	7 (37%)

𝑁 = number of Ewing’s patients; = confirmed complete response; PR: confirmed partial responses; SD: stable disease (best response); NA/NR: nonavailable/nonreported.